Hirofumi Kawamoto

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Tomoki Yamatsuji · 3 shared papers, 2022–2026 · strength 0.66
   • Paper Gastric metastasis from pancreatic ductal adenocarcinoma: a case report. DOI 10.1093/jscr/rjag233↗
   • Paper Clinical characteristics and prognosis of pancreatic ductal adenocarcinoma detected by health checkups versus symptomat… DOI 10.1038/s41598-026-67871-6↗
   • Paper Asymptomatic gangrenous cholecystitis diagnosed using contrast-enhanced ultrasonography in a patient with pancreatic ca… DOI 10.1016/j.radcr.2022.04.002↗
2. Tomohiro Tanikawa · 3 shared papers, 2022–2026 · strength 0.53
   • Paper Clinical characteristics and prognosis of pancreatic ductal adenocarcinoma detected by health checkups versus symptomat… DOI 10.1038/s41598-026-67871-6↗
   • Paper Efficacy of primary drainage by endoscopic ultrasound-guided biliary drainage for unresectable pancreatic adenocarcinom… DOI 10.1002/jgh3.12732↗
   • Paper Asymptomatic gangrenous cholecystitis diagnosed using contrast-enhanced ultrasonography in a patient with pancreatic ca… DOI 10.1016/j.radcr.2022.04.002↗
3. Ken Haruma · 3 shared papers, 2022–2026 · strength 0.53
   • Paper Clinical characteristics and prognosis of pancreatic ductal adenocarcinoma detected by health checkups versus symptomat… DOI 10.1038/s41598-026-67871-6↗
   • Paper Efficacy of primary drainage by endoscopic ultrasound-guided biliary drainage for unresectable pancreatic adenocarcinom… DOI 10.1002/jgh3.12732↗
   • Paper Asymptomatic gangrenous cholecystitis diagnosed using contrast-enhanced ultrasonography in a patient with pancreatic ca… DOI 10.1016/j.radcr.2022.04.002↗
4. Takashi Urano · 2 shared papers, 2022–2026 · strength 0.42
   • Paper Gastric metastasis from pancreatic ductal adenocarcinoma: a case report. DOI 10.1093/jscr/rjag233↗
   • Paper Asymptomatic gangrenous cholecystitis diagnosed using contrast-enhanced ultrasonography in a patient with pancreatic ca… DOI 10.1016/j.radcr.2022.04.002↗
5. Minoru Fujita · 2 shared papers, 2022–2026 · strength 0.38
   • Paper Clinical characteristics and prognosis of pancreatic ductal adenocarcinoma detected by health checkups versus symptomat… DOI 10.1038/s41598-026-67871-6↗
   • Paper Asymptomatic gangrenous cholecystitis diagnosed using contrast-enhanced ultrasonography in a patient with pancreatic ca… DOI 10.1016/j.radcr.2022.04.002↗
6. Ryo Katsumata · 2 shared papers, 2022 · strength 0.29
   • Paper Efficacy of primary drainage by endoscopic ultrasound-guided biliary drainage for unresectable pancreatic adenocarcinom… DOI 10.1002/jgh3.12732↗
   • Paper Asymptomatic gangrenous cholecystitis diagnosed using contrast-enhanced ultrasonography in a patient with pancreatic ca… DOI 10.1016/j.radcr.2022.04.002↗
7. Koji Yoshida · 1 shared paper, 2026 · strength 0.24
   • Paper Clinical characteristics and prognosis of pancreatic ductal adenocarcinoma detected by health checkups versus symptomat… DOI 10.1038/s41598-026-67871-6↗
8. Hironari Kato · 3 shared papers, 2011–2012 · strength 0.07
   • Paper Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemoth… DOI 10.1016/j.pan.2012.07.009↗
   • Paper Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients. DOI 10.1159/000330384↗
   • Paper A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II stud… DOI 10.1007/s10147-011-0237-z↗
9. Kazuhide Yamamoto · 3 shared papers, 2011–2012 · strength 0.07
   • Paper Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemoth… DOI 10.1016/j.pan.2012.07.009↗
   • Paper Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients. DOI 10.1159/000330384↗
   • Paper A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II stud… DOI 10.1007/s10147-011-0237-z↗
10. Ken Hirao · 2 shared papers, 2011–2012 · strength 0.05
    • Paper Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemoth… DOI 10.1016/j.pan.2012.07.009↗
    • Paper A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II stud… DOI 10.1007/s10147-011-0237-z↗
11. Koichiro Tsutsumi · 2 shared papers, 2011–2012 · strength 0.05
    • Paper Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemoth… DOI 10.1016/j.pan.2012.07.009↗
    • Paper A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II stud… DOI 10.1007/s10147-011-0237-z↗
12. Kazuhiro Nouso · 1 shared paper, 2012 · strength 0.03
    • Paper Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemoth… DOI 10.1016/j.pan.2012.07.009↗
13. Hiroyuki Okada · 1 shared paper, 2012 · strength 0.03
    • Paper Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemoth… DOI 10.1016/j.pan.2012.07.009↗
14. Kazuyuki Matsumoto · 1 shared paper, 2011 · strength 0.03
    • Paper Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients. DOI 10.1159/000330384↗
15. Ryo Harada · 1 shared paper, 2011 · strength 0.02
    • Paper A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II stud… DOI 10.1007/s10147-011-0237-z↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.